Efficacy and Safety of Durvalumab/Tremelimumab in Unresectable Hepatocellular Carcinoma as Immune Checkpoint Inhibitor Rechallenge Following Atezolizumab/Bevacizumab Treatment.

Takuya ShoGoki SudaMasatsugu OharaRisako KohyaTakashi SasakiSonoe YoshidaShunichi HosodaKoji OgawaTakashi KitagatayaOsamu MaeharaShunsuke OhnishiNaoki KawagishiMitsuteru NatsuizakaMasato NakaiMasaru BabaYoshiya YamamotoYoko TsukudaTakashi MeguroRen YamadaTomoe KobayashiTomofumi TakagiNaoya Sakamotonull null

Published in: Targeted oncology (2024)

Early safety and efficacy profiles of durvalumab/tremelimumab as ICI rechallenge are satisfactory.

Keyphrases

squamous cell carcinoma
locally advanced
radiation therapy